Cargando…

Cytotoxic FCER1G(+) innate-like T cells: new potential for tumour immunotherapy

Detalles Bibliográficos
Autores principales:	Morrish, Emma, Ruland, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243043/ https://www.ncbi.nlm.nih.gov/pubmed/35768418 http://dx.doi.org/10.1038/s41392-022-01061-4

Ejemplares similares

Prognostic and predictive value of FCER1G in glioma outcomes and response to immunotherapy
por: Xu, Houshi, et al.
Publicado: (2021)

FCER1G Gene Hypomethylation in Patients with Rheumatoid Arthritis
por: Podgórska, Dominika, et al.
Publicado: (2022)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

Innate immune signaling and immunothrombosis: New insights and therapeutic opportunities
por: Ryan, Tristram A. J., et al.
Publicado: (2022)

Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma
por: Fu, Lin, et al.
Publicado: (2020)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

IFNG, FCER1A, PCDHB10 expression as a new potential marker of efficacy in grass pollen allergen-specific immunotherapy
por: Romantowski, Jan, et al.
Publicado: (2021)

Innate lymphoid cells and cancer: Role in tumor progression and inhibition
por: Yuan, Xiaodong, et al.
Publicado: (2021)

Cytotoxic innate lymphoid cells sense tumor-derived IL-15: a novel mechanism of cancer immunosurveillance
por: Franz, Tobias, et al.
Publicado: (2022)

Prevention and treatment of COVID‐19 disease by controlled modulation of innate immunity
por: Schijns, Virgil, et al.
Publicado: (2020)

Likely a matter of time for Amyloid-β immunotherapy
por: Cunha, Andreia
Publicado: (2021)

Guards! Guards! How innate lymphoid cells ensure local law and order
por: Häfner, Sophia Julia
Publicado: (2021)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

High hopes and high honours for cancer immunotherapy
por: Häfner, Sophia Julia
Publicado: (2019)

Tumor‐derived microparticles in tumor immunology and immunotherapy
por: Ma, Jingwei, et al.
Publicado: (2020)

Fumarate hydratase inhibition activates innate immunity via mitochondrial nucleic acid release
por: Li, Xiang, et al.
Publicado: (2023)

A ‘fit’ microbiota to potentiate cancer immunotherapy
por: Rescigno, Maria
Publicado: (2015)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

Antigen targeting to dendritic cells: Still a place in future immunotherapy?
por: Stoitzner, Patrizia, et al.
Publicado: (2022)

Make immunological peace not war: Potential applications of tolerogenic dendritic cells
por: Walton, Emma Louise
Publicado: (2017)

Tumour travel tours – Why circulating cancer cells value company
por: Häfner, Sophia Julia
Publicado: (2020)

Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS‐CoV‐2 in mice
por: Ogger, Patricia P., et al.
Publicado: (2022)

Histamine and histamine receptor H1 (HRH1) axis: new target for enhancing immunotherapy response
por: Bai, Ziyi, et al.
Publicado: (2022)

New strategies for cancer immunotherapy: targeting regulatory T cells
por: Finotello, Francesca, et al.
Publicado: (2017)

The role of SPI1-TYROBP-FCER1G network in oncogenesis and prognosis of osteosarcoma, and its association with immune infiltration
por: Li, Jiahua, et al.
Publicado: (2022)

Gγ subunit AT1/GS3-the “code” of alkaline tolerance in main graminaceous crops
por: Ju, Chuanfeng, et al.
Publicado: (2023)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Constant regulation for stable CD8 T‐cell functional avidity and its possible implications for cancer immunotherapy
por: Gilfillan, Connie B., et al.
Publicado: (2021)

CD5: from antiquated T cell marker to immunotherapy’s new hope
por: Schwarz, Sandra, et al.
Publicado: (2023)

Immune modulation of HLA-G dimer in maternal-fetal interface
por: Kuroki, Kimiko, et al.
Publicado: (2007)

New strategy for cancer immunotherapy: using live engineered bacteria for metabolic modulation
por: Li, Tong, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Basal-bolus or premixed? Shedding light on optimal insulin regime for type 1 diabetes
por: Louise Walton, Emma
Publicado: (2018)

Cardiac hypertrophy: new role for endonuclease G
Publicado: (2011)

Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM
por: Bashore, Frances M., et al.
Publicado: (2023)

Local tissue development of type 1 innate lymphoid cells: guided by interferon-gamma
por: Conlon, Thomas M., et al.
Publicado: (2021)

Sinoatrial node pacemaker cells: cardiomyocyte- or neuron-like cells?
por: Zhou, Bin
Publicado: (2021)

SMIP-30, a potent and selective PPM1A inhibitor with potential to treat tuberculosis
por: Xu, Shujing, et al.
Publicado: (2022)

Life and death: the destiny of Phytophthora sojae determined by a receptor-like kinase
por: Wang, He, et al.
Publicado: (2023)

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
por: Ladanyi, Marc, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ktcodv334vrrshchcr3o5dn6m6